secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0000950170-25-032355
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MyoKardia terminates Fulcrum collaboration; Fulcrum loses future milestones and royalties
--------------------------------------------------------------------------------

- MyoKardia (BMS unit) terminated the collaboration agreement for convenience; effective June 26, 2025.
- Fulcrum forfeits all future milestone payments (up to $298.5M per target), royalties, and research cost reimbursement.
- Fulcrum had received $10M upfront, $2.5M prepaid research funding, and achieved a $2.5M preclinical milestone.
- Parties will continue obligations until June 26, 2025; no further revenues from the agreement after termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017025032355/0000950170-25-032355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017025032355/fulc-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-032355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer